论文部分内容阅读
目的:探讨嗅鞘细胞移植治疗运动神经元病/肌萎缩侧索硬化的安全性及有效性。方法:对8例运动神经元病/肌萎缩侧索硬化患者在脊髓病变处分两点共注入50μL嗅鞘细胞悬液,细胞数共约10×105个。结果:术前肌萎缩侧索硬化功能评分(ALSFRS)犤(18.6±7.9)分犦分别与术后2～4周犤(21.8±7.6)分犦比较,差异有显著性意义(t=-2.376,P=0.049),与术后3～6个月犤(21.5±7.6)分犦比较,差异无显著性意义(t=-2.025,P=0.083),8例患者的神经功能均稳定或改善。术后行肌电图检查的患者显示术后自发电位减少或消失,收缩时肌电波幅较术前明显降低,电位密度明显增加。结论:嗅鞘细胞移植安全可行,术后2～4周和3～6个月均能阻止或逆转运动神经元病肌萎缩侧索硬化的病情恶化。
Objective: To investigate the safety and efficacy of olfactory ensheathing cell transplantation in the treatment of motor neuron disease / amyotrophic lateral sclerosis. Methods: Eight patients with motor neuron disease / amyotrophic lateral sclerosis were injected with 50 μL of OECs suspension at two points in myelopathy. The total number of cells was about 10 × 105. Results: The ALSFRS 犤 (18.6 ± 7.9) 术 was significantly higher than that of 犤 (21.8 ± 7.6) 2 after operation at 2-4 weeks (t = -2.376 , P = 0.049). There was no significant difference between the two groups (P = 0.049, t = -2.025, P = 0.083). The neurological function of 8 patients was stable or improved . Electromyography patients after surgery showed that spontaneous potential after surgery to reduce or disappear when the amplitude of myoelectric contraction was significantly lower than before surgery, the potential density increased significantly. Conclusion: Olfactory ensheathing cells transplantation is safe and feasible. Both 2-4 weeks and 3-6 months after operation can prevent or reverse the worsening of amyotrophic lateral sclerosis of motor neuron disease.